AGP Picks
View all

Investor News Updates: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Investor News Updates.

Press releases published on June 14, 2026

RISE OF CONCIERGE SERVICES TRANSFORMS LUXURY LIVING IN QUEENSLAND, AUSTRALIA
Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02
MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
ディファイアンスETFs、シーボーBZX取引所におけるディファイアンス・デイリー2XスペースETF (SPCL) の一時取引停止を発表
스페이스X 2배 레버리지 ETF (SPCL), Cboe BZX 거래소 조치로 거래 일시 중지했다고 Defiance ETFs가 발표
Defiance ETFs Umumkan Penggantungan Sementara Dagangan Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.
Defiance ETFs 宣布 Defiance Daily 2X Space ETF (SPCL) 在 Cboe BZX Exchange, Inc. 暂停交易
Defiance ETFs 宣佈,Defiance Daily 2X Space ETF (SPCL) 暫時停止於 Cboe BZX Exchange, Inc. 進行交易
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Salomon Unfolds the Next Chapter of ROAD TO THE FUTURE in Shanghai
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL
Air Canada and the IAMAW Reach Tentative Agreement on New Contract
Air Canada et l’AIMTA concluent une entente de principe sur une nouvelle convention collective

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Investor News Updates

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.